Vertex Pharmaceuticals

VRTX · NASDAQ

$514.65+$12.70 (+2.53%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $501.95

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Employees: 6,400
Headquarters: Boston, Massachusetts
Listed: Jul 24, 1991
Sector: Health Care
Industry: Biotechnology
Website: vrtx.com

Leadership

Vertex Pharmaceuticals executives
Name	Title	Since	Age
Jeffrey Leiden	—	2009	69
Reshma Kewalramani	—	2018	52
Charles Wagner	—	—	57
David Altshuler	—	2012	60
E. Morrow Atkinson	—	—	59
Jonathan Biller	—	—	61
Carmen Bozic	—	—	62
Duncan Mckechnie	—	—	56
Amit Sachdev	—	—	57
Ourania Tatsis	—	—	55
Kristen Ambrose	—	—	48
Joy Liu	—	—	46
Bruce Sachs	—	—	65
Sangeeta Bhatia	—	—	56
Lloyd Carney	—	—	63
Alan Garber	—	—	69
Michel Lagarde	—	—	51
Diana Mckenzie	—	—	60
Jennifer Schneider	—	—	50
Nancy Thornberry	—	—	68
Suketu Upadhyay	—	—	56
Susie Lisa	—	2023	—

Revenue by product and region

Fiscal year ended Dec 31, 2025: $12.00B total revenue

By product

Product revenues, net$11.97B99.7%
Other revenues$30.70M0.3%

By region

United States$7.55B62.9%
Total revenues outside of the United States$4.45B37.1%
Europe$3.46B28.8%
Other$992.40M8.3%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Vertex Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
McKesson Corporation MCK	Customer	US	0.94
Cigna Corporation CI	Customer	US	0.81
Royalty Pharma A RPRX	Supplier	US	0.35
Tufin Software Technologies Ltd. TUFN	Supplier	US	0.34
Brooks Automation, Inc. BRKS	Supplier	—	0.25
Concert Pharmaceuticals CNCE	Supplier	US	-0.09
Merck MRK.DE	Supplier and customer	DE	-0.27
Walgreens Boots Alliance, Inc. WBA	Customer	US	-0.33
MERCK Kommanditgesellschaft auf Aktien MKGAF	Supplier	—	-0.41
Grid Dynamics Holdings A GDYN	Supplier	US	-0.58

Similar companies

Companies in the same industry as Vertex Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.